Ascendis Pharma A/S (FRA:A71)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	616.04	559.54	392.16	444.77	446.27
Short-Term Investments	-	-	7.28	290.69	235.8
Cash & Short-Term Investments	616.04	559.54	399.44	735.46	682.06
Cash Growth	10.10%	40.08%	-45.69%	7.83%	-5.11%
Accounts Receivable	141.33	166.28	35.87	11.91	2.2
Other Receivables	16.36	11.16	19.9	13.72	20.99
Receivables	157.7	177.44	55.77	25.63	23.19
Inventory	301.53	295.61	208.93	130.67	75.41
Prepaid Expenses	33.72	28.27	38.58	31.72	25.23
Total Current Assets	1,109	1,061	702.72	923.47	805.89
Property, Plant & Equipment	146.48	98.71	110.63	129.1	126.05
Long-Term Investments	32.53	13.58	5.69	30.42	145.91
Goodwill	3.5	3.5	3.5	-	3.5
Other Intangible Assets	0.22	0.53	0.92	4.83	1.78
Other Long-Term Assets	10.87	2.32	2.13	1.92	1.81
Total Assets	1,303	1,179	825.59	1,090	1,085

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	90.66	96.39	94.57	101.03	59.42
Accrued Expenses	-	-	41.18	31.99	29.95
Current Portion of Long-Term Debt	466.09	476.05	407.1	399.19	-
Current Portion of Leases	20.44	15.48	14.17	13.79	7
Current Income Taxes Payable	6.43	1.22	2.3	5.49	0.2
Current Unearned Revenue	4.94	0.94	1.18	-	2.6
Other Current Liabilities	480.83	317.78	176.02	165.29	1.19
Total Current Liabilities	1,069	907.86	736.51	716.78	100.36
Long-Term Debt	254.17	287.53	138.38	-	-
Long-Term Leases	131.09	77.55	84.62	95.4	97.97
Long-Term Unearned Revenue	1.12	5	5.95	14.21	2.96
Long-Term Deferred Tax Liabilities	9.62	7.26	5.83	-	-
Total Liabilities	1,465	1,285	971.28	826.39	201.29

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	8.32	8.15	7.75	7.68	7.65
Additional Paid-In Capital	2,531	2,444	2,123	2,113	2,108
Retained Earnings	-2,700	-2,560	-2,277	-1,860	-1,236
Treasury Stock	-0.08	-0.11	-0.15	-0.15	-0.02
Comprehensive Income & Other	-1.76	1.78	0.72	3.45	3.78
Shareholders' Equity	-162.82	-105.71	-145.7	263.35	883.64
Total Liabilities & Equity	1,303	1,179	825.59	1,090	1,085

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	871.79	856.62	644.27	508.38	104.96
Net Cash (Debt)	-255.75	-297.07	-244.83	234.57	684.66
Net Cash Growth	-	-	-	-65.74%	-7.74%
Net Cash Per Share	-4.22	-5.13	-4.35	4.18	12.50
Filing Date Shares Outstanding	61.38	59.84	56.61	56.04	56.78
Total Common Shares Outstanding	61.38	59.84	56.61	56.04	56.78
Working Capital	39.59	153	-33.79	206.69	705.53
Book Value Per Share	-2.65	-1.77	-2.57	4.70	15.56
Tangible Book Value	-166.53	-109.73	-150.12	258.52	878.36
Tangible Book Value Per Share	-2.71	-1.83	-2.65	4.61	15.47
Machinery	37.62	32.91	38.86	-	25.77
Leasehold Improvements	7.05	20.3	19.38	-	18.07

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Apr 20, 2026

Data Sources Report a data error